Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXER1 | Q8TDS5 | 3/20 | 0.49 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 8/20 | 0.43 |
| ▸ | PPARD | Q03181 | 5/20 | 0.43 |
| ▸ | KMO | O15229 | 4/20 | 0.43 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
| ▸ | PPARA | Q07869 | 4/20 | 0.41 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL968306 | 0.95 | OXER1 (0.45) | OXER1MAPK8PPARGPPARDKMO | |
| SCHEMBL961862 | 0.88 | PTGDR2 (0.48) | OXER1MAPK8KMOPTGDR2 | |
| SCHEMBL962579 | 0.87 | KMT2A (0.41) | OXER1MAPK8PTGDR2 | |
| SCHEMBL964906 | 0.85 | KMT2A (0.42) | MAPK8PTGDR2 | |
| SCHEMBL965783 | 0.85 | KDM4E (0.43) | MAPK8 | |
| SCHEMBL961483 | 0.84 | HTR2A (0.37) | OXER1MAPK8PTGDR2 | |
| SCHEMBL5120369 | 0.84 | PHGDH (0.38) | OXER1MAPK8KMOPTGDR2 | |
| SCHEMBL964505 | 0.83 | PTGDR2 (0.39) | OXER1MAPK8KMOPTGDR2 | |
| SCHEMBL964487 | 0.83 | HTR2A (0.38) | MAPK8PTGDR2 | |
| SCHEMBL4553742 | 0.83 | MAPK8 (0.37) | MAPK8PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-01-13 | — | — | US | disclosed |
| EP-2118066-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | Takeda Pharmaceutical Company Limited (JP) | 2009-11-18 | — | — | EP | disclosed |
| WO-2008099794-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-21 | — | — | WO | disclosed |
| US-20080194617-A1 | Fused ring compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194617-A1 | Fused ring compound | SLC5A1, SLC5A2, GPR119 | OXER1 2529/4885MAPK8 2053/4885PPARG 248/4885 |
| US-20110009384-A1 | FUSED RING COMPOUNDS AS PARTIAL AGONISTS OF PPAR-GAMMA | PPARA, PPARD, PPARG | OXER1 877/4885MAPK8 2186/4885PPARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.